DNA methylation markers for endometrial cancer detection in minimally invasive samples: a systematic review

Rianne van den Helder; Birgit Mm Wever; Jip A van Trommel; Johannes Cf Ket; Maaike Cg Bleeker; Renske Dm Steenbergen

doi:10.2217/epi-2020-0164

DNA methylation markers for endometrial cancer detection in minimally invasive samples: a systematic review

Rianne van den Helder
, Birgit Mm Wever
, Jip A van Trommel
, Johannes Cf Ket
, Maaike Cg Bleeker
, Renske Dm Steenbergen

National Institute for Public Health and the Environment (RIVM), Centre for Infectious Disease Control, Antonie van Leeuwenhoeklaan 9, Bilthoven, the Netherlands; Amsterdam UMC, Vrije Universiteit, Department of Pathology, Cancer Center Amsterdam, De Boelelaan 1117, Amsterdam, the Netherlands.
Medical Library, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.

Research output: Contribution to journal › Review article › Academic › peer-review

Abstract

Aim: DNA methylation testing for endometrial cancer detection in minimally invasive specimens is a promising tool to improve screening and diagnostic procedures. Available literature was systematically reviewed to assess the potential of this approach and define methylation markers deserving further development. Methods: A systematic search up to March 31 2020 was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Results: 15 methylation markers with an area under the curve value of ≥ 0.80 for endometrial cancer detection in cytological specimens were selected from nine studies. Conclusion: Detection of methylation markers in cytological samples indicate the feasibility of minimally invasive testing methods, potentially guiding diagnosis and detection of endometrial cancer in high-risk women and in cancer screening programs.

Original language	English
Pages (from-to)	1661-1672
Number of pages	12
Journal	Epigenomics
Volume	12
Issue number	18
DOIs	https://doi.org/10.2217/epi-2020-0164
Publication status	Published - 1 Sept 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

DNA methylation
biomarkers
cancer detection
endometrial cancer
minimally invasive

Access to Document

10.2217/epi-2020-0164

Cite this

@article{2e77e5d6143643b6aff9a2729e1ad69a,

title = "DNA methylation markers for endometrial cancer detection in minimally invasive samples: a systematic review",

abstract = "Aim: DNA methylation testing for endometrial cancer detection in minimally invasive specimens is a promising tool to improve screening and diagnostic procedures. Available literature was systematically reviewed to assess the potential of this approach and define methylation markers deserving further development. Methods: A systematic search up to March 31 2020 was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Results: 15 methylation markers with an area under the curve value of ≥ 0.80 for endometrial cancer detection in cytological specimens were selected from nine studies. Conclusion: Detection of methylation markers in cytological samples indicate the feasibility of minimally invasive testing methods, potentially guiding diagnosis and detection of endometrial cancer in high-risk women and in cancer screening programs.",

keywords = "DNA methylation, biomarkers, cancer detection, endometrial cancer, minimally invasive",

author = "\{den Helder\}, \{Rianne van\} and Wever, \{Birgit Mm\} and \{van Trommel\}, \{Jip A\} and Ket, \{Johannes Cf\} and Bleeker, \{Maaike Cg\} and Steenbergen, \{Renske Dm\}",

note = "Funding Information: This work was supported by Hanarth Foundation and Weijerhorst Foundation, who provided financial support for the conduct of the research and had no role in conducting the research and preparation of the manuscript. RDM Steenbergen has a minority share in Self-screen B.V., a spin-off company of Amsterdam UMC, location VUmc. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. Publisher Copyright: {\textcopyright} 2020 Future Medicine Ltd. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",

year = "2020",

month = sep,

day = "1",

doi = "10.2217/epi-2020-0164",

language = "English",

volume = "12",

pages = "1661--1672",

journal = "Epigenomics",

issn = "1750-1911",

publisher = "Future Medicine Ltd.",

number = "18",

}

TY - JOUR

T1 - DNA methylation markers for endometrial cancer detection in minimally invasive samples

T2 - a systematic review

AU - den Helder, Rianne van

AU - Wever, Birgit Mm

AU - van Trommel, Jip A

AU - Ket, Johannes Cf

AU - Bleeker, Maaike Cg

AU - Steenbergen, Renske Dm

N1 - Funding Information: This work was supported by Hanarth Foundation and Weijerhorst Foundation, who provided financial support for the conduct of the research and had no role in conducting the research and preparation of the manuscript. RDM Steenbergen has a minority share in Self-screen B.V., a spin-off company of Amsterdam UMC, location VUmc. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. Publisher Copyright: © 2020 Future Medicine Ltd. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.

PY - 2020/9/1

Y1 - 2020/9/1

N2 - Aim: DNA methylation testing for endometrial cancer detection in minimally invasive specimens is a promising tool to improve screening and diagnostic procedures. Available literature was systematically reviewed to assess the potential of this approach and define methylation markers deserving further development. Methods: A systematic search up to March 31 2020 was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Results: 15 methylation markers with an area under the curve value of ≥ 0.80 for endometrial cancer detection in cytological specimens were selected from nine studies. Conclusion: Detection of methylation markers in cytological samples indicate the feasibility of minimally invasive testing methods, potentially guiding diagnosis and detection of endometrial cancer in high-risk women and in cancer screening programs.

AB - Aim: DNA methylation testing for endometrial cancer detection in minimally invasive specimens is a promising tool to improve screening and diagnostic procedures. Available literature was systematically reviewed to assess the potential of this approach and define methylation markers deserving further development. Methods: A systematic search up to March 31 2020 was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Results: 15 methylation markers with an area under the curve value of ≥ 0.80 for endometrial cancer detection in cytological specimens were selected from nine studies. Conclusion: Detection of methylation markers in cytological samples indicate the feasibility of minimally invasive testing methods, potentially guiding diagnosis and detection of endometrial cancer in high-risk women and in cancer screening programs.

KW - DNA methylation

KW - biomarkers

KW - cancer detection

KW - endometrial cancer

KW - minimally invasive

UR - https://www.scopus.com/pages/publications/85092120228

U2 - 10.2217/epi-2020-0164

DO - 10.2217/epi-2020-0164

M3 - Review article

SN - 1750-1911

VL - 12

SP - 1661

EP - 1672

JO - Epigenomics

JF - Epigenomics

IS - 18

ER -

DNA methylation markers for endometrial cancer detection in minimally invasive samples: a systematic review

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this